skip to the main content area of this page

Analogue Control for CANADA

Analogue Control
The Controlled Drugs and Substances Act (CDSA), 1996
The Controlled Drugs and Substances Act (S.C. 1996, c. 19) contains not only a list of substances individually listed for purposes of control, but in some cases, it is possible that an existing schedule entry could include NPS by virtue of the fact that the substance in question is a salt, derivative, isomer and analogue and salt of derivatives, isomers and analogues of a substance already listed in one of the Schedules. This is determined on a case by case basis via the status decision process which assesses the chemical structure and/or pharmacological activity of the NPS against that of existing controlled substances. The status decision process has allowed Canada to consider approximately 70 NPS as controlled. For example, methylone is considered to be an analogue of amphetamine, which is included in Schedule I to the CDSA. Unique item in Schedule II to the CDSA which deals with cannabis allows the Minister of Health to deem any similar synthetic preparation of cannabis to be a controlled substance. For example, JWH-018 is considered to be a similar synthetic preparation of cannabis and is therefore considered to be included in Schedule II to the CDSA. The challenge however is that in order for a substance to be deemed a similar synthetic preparation, there has to be scientific data showing that the substance has a similar pharmacological activity profile to THC, and often that scientific data is not available. Amphetamines and its analogues are controlled under Item 1, Schedule III of the Controlled Drugs and Substances Act

If you have any further information or any amendments to the information provided on this page, please send an email to Global SMART (